Revolution Medicines (RVMD)
(Delayed Data from NSDQ)
$47.94 USD
+1.80 (3.90%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $47.91 -0.03 (-0.06%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RVMD 47.94 +1.80(3.90%)
Will RVMD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RVMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RVMD
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
RVMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates
Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?
Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates
Other News for RVMD
Revolution Medicines price target raised by $2 at Barclays, here's why
Barclays Remains a Buy on Revolution Medicines (RVMD)
Revolution Medicines price target raised by $10 at Oppenheimer, here's why
Revolution Medicines price target raised by $12 at H.C. Wainwright, here's why
Revolution Medicines price target raised by $7 at BofA, here's why